This paper discusses the need for a health economics perspective and some of the central methodological issues raised by economic appraisals, including cost-effectiveness and cost-utility analyses. It illustrates how cost-effectiveness studies can inform policy and practice decisions concerning the treatment of schizophrenia, focusing on five generic evaluation questions commonly raised. Examples are drawn from recent and current UK research.
No takes yet. Share an insight, caveat, or question.
A 1996 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: